$599

Imeglimin Approved in Japan as “Twymeeg”; Diamyd Q1 ’21 Business Update

Two cardiometabolic-related news items have been observed: Poxel and Sumitomo Dainippon Pharma announced Japanese approval of 500mg oral imeglimin, branded as “Twymeeg,” for the treatment of T2DM; and Diamyd announced its quarterly report for Q3 ’21. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here